Alzheimer's Tau Biomarker SMAs (p-tau, BD-tau)
Alzheimer's Disease
Research/CommercialActive in RUO/Partner Assays
Key Facts
Indication
Alzheimer's Disease
Phase
Research/Commercial
Status
Active in RUO/Partner Assays
Company
About Bioventix
Bioventix is a specialist biotechnology company focused on the development and supply of high-affinity sheep monoclonal antibodies for the global in-vitro diagnostics (IVD) industry. Founded in 2004 and listed on the London AIM market, its core strategy is to identify diagnostic assays with unmet needs for better antibodies, develop superior SMAs, and license them to major diagnostic partners, generating stable, high-margin royalty revenue. The company has achieved consistent profitability and growth by leveraging its unique technological niche to become a critical, behind-the-scenes supplier to nearly all major global immunodiagnostics companies.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | Johnson and Johnson Innovative Medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |
| PMN310 | ProMIS Neurosciences | Phase 1b |